Q-omics provides the consensus-scored GFPT1 profile across patient tissues and cancer cell-line models. GFPT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GFPT1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, GFPT1 RNA expression shows 21,344 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where GFPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFPT1 survival associations across molecular data types. GFPT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFPT1 RNA expression–survival associations across cancer types. High GFPT1 expression shows unfavorable associations in KIRP, UVM, ACC and BLCA, but favorable associations in KIRC and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GFPT1 RNA expression.
This table summarizes GFPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GFPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFPT1 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD, LIHC, LUSC and STAD. The BLCA box plot shows higher GFPT1 RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with GFPT1 in patient tissues and cancer cell lines. In patient samples, GFPT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GFPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
